Bullous Pemphigoid in Patients with Non-small-cell Lung Cancer Complicated by Diabetes Mellitus Receiving Dipeptidyl Peptidase-4 Inhibitors and Immune Checkpoint Inhibitors: A Case Report of Two Patients and Review of Literature

Koki Nakashima; Yoshiki Demura; Satomi Kimura; Koji Yamaoka; Masahiro Oi; Tomoaki Sonoda; Toshihiko Tada; Tamotsu Ishizuka

doi:10.2169/internalmedicine.5090-24

Koki Nakashima, Yoshiki Demura, Satomi Kimura, Koji Yamaoka, Masahiro Oi, Tomoaki Sonoda, Toshihiko Tada, Tamotsu Ishizuka

著者情報

キーワード: bullous pemphigoid, dipeptidyl peptidase-4 (DPP-4), DPP-4 inhibitor, non-small-cell lung cancer (NSCLC), immune checkpoint inhibitor (ICI), immune-related adverse event (irAE)

ジャーナルオープンアクセス早期公開

論文ID: 5090-24

DOI https://doi.org/10.2169/internalmedicine.5090-24

詳細

抄録

Dipeptidyl peptidase-4 inhibitors (DPP-4is) are shown to be associated with the development of bullous pemphigoid (BP). Immune checkpoint inhibitors (ICIs) can lead to BP development. Therefore, the combination of DPP-4is and ICIs may predispose an individual to developing BP; however, few reports have focused on this issue. We herein report two patients with non-small-cell lung cancer complicated by diabetes mellitus (DM) who developed BP while receiving DPP-4is and ICIs. The clinical course of these patients suggests that the combination of DPP-4is and ICIs may carry a potential risk of BP development.

責任著者(Corresponding author)

J-STAGEへの登録はこちら（無料）